...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Graefe's archive for clinical and experimental ophthalmology: Albrecht von Graefes Archiv fur klinische und experimentelle Opthalmologie >Repeated IL-10 measurement in aqueous humor and OCT imaging are valuable tools to monitor intraocular lymphoma treated with intravitreal injections of methotrexate.
【24h】

Repeated IL-10 measurement in aqueous humor and OCT imaging are valuable tools to monitor intraocular lymphoma treated with intravitreal injections of methotrexate.

机译：在房水和OCT成像中重复测量IL-10是监测玻璃体内注射甲氨蝶呤治疗的眼内淋巴瘤的重要工具。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Primary intraocular lymphoma (PIOL) is a rare disease (1/100,000) whose incidence has been increasing in the past 2 decades [1]. The survival prognosis of PIOL remains reserved due to frequent disease extension to the CNS within 3 years [2]. Systemic chemotherapies such as intravenous methotrexate (MTX) are the classical first-line treatment [3]. However, the systemic route of administration is related to serious haematological side-effects, especially because high doses are necessary to reach efficient vitreous concentrations (>0.5 mumol/l) [4]. In order to overcome these drawbacks, intravitreal MTX injections have been proposed in cases of isolated PIOL with successful outcomes and acceptable tolerance [5]. Nevertheless, the optimal follow-up scheme for this treatment option remains to be defined [6]. hi the present study, we report the cases of two patients treated with intravitreal injections of MTX with a 1-year follow-up. Pharmacokinetics of ocular MTX were assessed by MTX measurements in aqueous humor. Long-term efficacy was monitored by monthly IL-10 measurements and optical coherence tomography (OCT) examinations. Serial IL-10 measurements combined with OCT examinations enabled the early detection of a PIOL recurrence.
机译：原发性眼内淋巴瘤（PIOL）是一种罕见的疾病（1 / 100,000），其发病率在过去的20年中一直在增加[1]。 PIOL的生存预后仍然是保留的，这是由于3年内疾病频繁扩展到CNS [2]。全身性化学疗法，例如静脉甲氨蝶呤（MTX）是经典的一线治疗方法[3]。但是，全身性给药途径与严重的血液学副作用有关，特别是因为需要高剂量才能达到有效的玻璃体浓度（> 0.5μmol/ l）[4]。为了克服这些缺点，有人提出在孤立的PIOL情况下玻璃体MTX注射具有成功的结果和可接受的耐受性[5]。尽管如此，该治疗方案的最佳随访方案仍有待确定[6]。在本研究中，我们报告了两名接受玻璃体腔注射MTX治疗的患者，并进行了1年的随访。眼MTX的药代动力学通过房水中的MTX测量来评估。通过每月IL-10测量和光学相干断层扫描（OCT）检查来监测长期疗效。连续的IL-10测量与OCT检查相结合，可以及早发现PIOL复发。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号